Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 21, 2021
Event: Filing of a prospectus supplement for an at-the-market equity offering.
Key Financial Metrics
This filing does not report historical financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the proposed capital raise:
- Offering Size: Up to $75,000,000 in aggregate offering price.
- Instrument: Shares of common stock, par value $0.001 per share.
- Sales Agent: H.C. Wainwright & Co., LLC.
Material Changes
The filing announces the initiation of a new equity offering under the Company's existing at-the-market program. This represents a potential increase in share count and capital resources, contingent upon the sale of shares. No material changes to historical financial results are reported in this document.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use net proceeds for:
- Research and development related to product candidates.
- Manufacturing of products.
- Working capital and general corporate purposes.
Flexibility: The Board of Directors reserves the right to reallocate proceeds based on business developments. The Company states it cannot specify with certainty all particular uses for the net proceeds at this time.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the actual number of shares sold and net proceeds received, as the $75 million figure represents the maximum aggregate offering price, not a guaranteed amount.
- Review the Common Stock Sales Agreement with H.C. Wainwright & Co., LLC for commission rates and sales terms.
- Monitor subsequent filings for the actual allocation of proceeds to R&D versus general corporate purposes.
- Check the Company's Form S-3 Registration Statement (filed March 16, 2021, amended June 15, 2021) for broader capitalization details.